甲氨蝶呤的预期清除率是多少？儿童恶性肿瘤大剂量甲氨蝶呤治疗药物监测参考指南。

IF 2.4 3区医学 Q2 HEMATOLOGY

Pediatric Blood & Cancer Pub Date : 2025-04-20 DOI:10.1002/pbc.31744

Zachary L Taylor, Tamara P Miller, Sarah G Board, Ethan A Poweleit, Ashley Chavana, Allison Weisnicht, Austin L Brown, Melanie B Bernhardt, Eric S Schafer, Maureen M O'Brien, Sharon M Castellino, Laura B Ramsey

{"title":"甲氨蝶呤的预期清除率是多少？儿童恶性肿瘤大剂量甲氨蝶呤治疗药物监测参考指南。","authors":"Zachary L Taylor, Tamara P Miller, Sarah G Board, Ethan A Poweleit, Ashley Chavana, Allison Weisnicht, Austin L Brown, Melanie B Bernhardt, Eric S Schafer, Maureen M O'Brien, Sharon M Castellino, Laura B Ramsey","doi":"10.1002/pbc.31744","DOIUrl":null,"url":null,"abstract":"High-dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols. Using modeling and simulation of real-world data, we determined the expected MTX concentrations at common time points from the start of infusion (24, 36, 42, 48, 60, and 72 hours) and the time that each patient would reach a typical discharge threshold (0.4, 0.2, 0.15, and 0.10 µM). These data provide a reference for MTX concentrations for common pediatric protocols.","PeriodicalId":19822,"journal":{"name":"Pediatric Blood & Cancer","volume":" ","pages":"e31744"},"PeriodicalIF":2.4000,"publicationDate":"2025-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies.\",\"authors\":\"Zachary L Taylor, Tamara P Miller, Sarah G Board, Ethan A Poweleit, Ashley Chavana, Allison Weisnicht, Austin L Brown, Melanie B Bernhardt, Eric S Schafer, Maureen M O'Brien, Sharon M Castellino, Laura B Ramsey\",\"doi\":\"10.1002/pbc.31744\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"High-dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols. Using modeling and simulation of real-world data, we determined the expected MTX concentrations at common time points from the start of infusion (24, 36, 42, 48, 60, and 72 hours) and the time that each patient would reach a typical discharge threshold (0.4, 0.2, 0.15, and 0.10 µM). These data provide a reference for MTX concentrations for common pediatric protocols.\",\"PeriodicalId\":19822,\"journal\":{\"name\":\"Pediatric Blood & Cancer\",\"volume\":\" \",\"pages\":\"e31744\"},\"PeriodicalIF\":2.4000,\"publicationDate\":\"2025-04-20\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pediatric Blood & Cancer\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1002/pbc.31744\",\"RegionNum\":3,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q2\",\"JCRName\":\"HEMATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pediatric Blood & Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1002/pbc.31744","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"HEMATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

小儿白血病、淋巴瘤和骨肉瘤的高剂量甲氨蝶呤剂量和输注时间因治疗方案而异。支持性护理干预取决于患者是否消除甲氨蝶呤（MTX）。因此，跨协议建立预期的MTX消除是很重要的。通过对真实世界数据的建模和模拟，我们确定了从输注开始（24、36、42、48、60和72小时）的常见时间点的预期MTX浓度，以及每个患者达到典型放电阈值的时间（0.4、0.2、0.15和0.10µM）。这些数据为常见儿科方案的甲氨蝶呤浓度提供了参考。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

What Is the Expected Clearance of Methotrexate? A Therapeutic Drug Monitoring Reference Guide for High-Dose Methotrexate Use in Pediatric Malignancies.

High-dose methotrexate dosage and infusion durations differ across treatment protocols for pediatric leukemia, lymphoma, and osteosarcoma. Supportive care interventions are dependent on a patient's elimination of methotrexate (MTX). Therefore, it is important to establish the expected MTX elimination across protocols. Using modeling and simulation of real-world data, we determined the expected MTX concentrations at common time points from the start of infusion (24, 36, 42, 48, 60, and 72 hours) and the time that each patient would reach a typical discharge threshold (0.4, 0.2, 0.15, and 0.10 µM). These data provide a reference for MTX concentrations for common pediatric protocols.

求助全文

通过发布文献求助，成功后即可免费获取论文全文。去求助

来源期刊

Pediatric Blood & Cancer 医学-小儿科

CiteScore

4.90

自引率

9.40%

发文量

546

审稿时长

1.5 months

期刊介绍： Pediatric Blood & Cancer publishes the highest quality manuscripts describing basic and clinical investigations of blood disorders and malignant diseases of childhood including diagnosis, treatment, epidemiology, etiology, biology, and molecular and clinical genetics of these diseases as they affect children, adolescents, and young adults. Pediatric Blood & Cancer will also include studies on such treatment options as hematopoietic stem cell transplantation, immunology, and gene therapy.